Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement

Inclusion Criteria: 1. Patients undergoing elective solitary SAVR with bioprosthesis 2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery 3. No prior use of HMG-CoA reductase inhibitors the last 3 months and at least 7 days prior to the time of surgery 4. Age \>60 years 5. Willingness and provision of informed consent to be randomized Exclusion Criteria: 1. Prior history of atrial fibrillation 2. Prior history of cardiac surgery 3. Known adverse reaction to HMG-CoA reductase inhibitors 4. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit) 5. Creatinine \>200 µmol/L 6. Known intolerance to statins or history of muscle toxicity with statins 7. Known intolerance to any of the excipients in Lipistad 8. Treatment with anti-viral medicine (glecaprevir/pibrentasvir) for hepatitis